Fiche société
Tharick Pascoal
Traitements, essais et publications liés.
Traitements4programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
4| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 18F-Flortaucipir radiopharmaceuticalThe purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates. | Alzheimer | Phase 1 | À vérifier | United States, Canada, Spain | À vérifier |
| 18F-MK-6240 radiopharmaceuticalThe purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates. | Alzheimer | Phase 1 | À vérifier | United States, Canada, Spain | À vérifier |
| Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates. | Alzheimer | Phase 1 | À vérifier | United States, Canada, Spain | À vérifier |
| 18F-Flortaucipir radiopharmaceuticalThe purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates. | Alzheimer | Phase 1 | À vérifier | United States, Canada, Spain | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| 18F-Flortaucipir radiopharmaceutical | Alzheimer | Phase 1 | NCT05361382 | Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||